Gerald Clarke | 06/21/2013
Peter Staller Director of Oncology Research at Epitherapeutics talks to Pharma IQ about the differences between traditional drug development techniques and those required for development of a epigenetic therapy. He also discusses epigenetics as a growing area for finding druggable targets and the maturity of the field.
Have Your Say
Rate this feature and give us your feedback in the comments section below
To continue reading this story Click Here
Upcoming Events
DigIT Pharma AI Commercial Excellence & Health 2025
September 1 - 3 2025
Palace Hotel Berlin, Germany
Register Now |
View Agenda |
Learn More
GenAI Life Science & Health 2025
September 1 - 3 2025
Berlin, Germany
Register Now |
View Agenda |
Learn More